Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Heather Brillhart

Obstetrics Silver Spring, MD Medical Doctor

NPI 1538502349 CMS profile 3966559

10801 Lockwood Dr Ste 320, Silver Spring, MD 20901

Open in the dashboard

General payments

$2,223

111 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Brillhart of Silver Spring, MD is reported in the CMS Open Payments database as having received $2,223 across 111 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $245 11
2024 General $312 15
2023 General $254 14
2022 General $418 21
2021 General $624 28
2020 General $191 10
2019 General $180 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Brillhart
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Heather Brillhart were reported at $245. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Heather Brillhart Obstetrics median Middle half National median
2019 $180 $177 $60–$381 $163
2020 $191 $92 $35–$201 $114
2021 $624 $125 $40–$351 $132
2022 $418 $186 $65–$448 $149
2023 $254 $183 $61–$451 $160
2024 $312 $176 $62–$406 $164
2025 $245 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $515 30 payments
  2. Astellas Pharma US Inc $194 8 payments
  3. Vermillion, Inc. $180 2 payments
  4. TherapeuticsMD, Inc. $135 7 payments
  5. Mayne Pharma Inc. $129 6 payments
  6. Cumberland Pharmaceuticals, Inc. $107 2 payments
  7. Organon LLC $107 6 payments
  8. Millicent US Inc $95 5 payments
  9. Daiichi Sankyo Inc. $87 5 payments
  10. Pfizer Inc. $85 5 payments
  11. Other $588 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,223 111 payments
Products named General payments · program years 2019–2025
  1. LO LOESTRIN FE $267 15 payments
  2. ORILISSA $258 16 payments
  3. OVA1 $180 2 payments
  4. Veozah $176 7 payments
  5. ORIAHNN $158 9 payments
  6. KRISTALOSE $107 2 payments
  7. NEXPLANON $93 5 payments
  8. INTRAROSA $80 4 payments
  9. FEMRING $80 4 payments
  10. INJECTAFER $71 4 payments
  11. Other $1,212 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

22

Median for Obstetrics & Gynecology: 65

Drug cost

$228

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

0%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluconazole Generic 11 $129
Alendronate Sodium Generic 11 $99

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$10,195

Medicare's payments for the services billed

Medicare patients

75

Average age 72

Services billed

168

75 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Osteoporosis 37%
Diabetes 23%
Depression 20%
Cancer 17%
Ischemic heart disease 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $106
$106 — —
FEMRING
  • MILLICENT US INC $40
$40 — —
INTRAROSA
  • MILLICENT US INC $40
$40 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $25
$25 — —
GARDASIL 9
  • Merck Sharp & Dohme Corporation $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

111 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record